---
title: "Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290956992.md"
description: "A biotechnology company, Avalo Therapeutics, Inc. (Nasdaq: AVTX), headquartered in Wayne, Pennsylvania, specializing in therapeutics for immune-mediated inflammatory diseases, revealed that it is set to join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index. This change will come into effect after the closure of U.S. stock markets on June 26, 2026."
datetime: "2026-06-26T11:01:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290956992.md)
  - [en](https://longbridge.com/en/news/290956992.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290956992.md)
generator: "portal-rs"
---

# Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

A biotechnology company, Avalo Therapeutics, Inc. (Nasdaq: AVTX), headquartered in Wayne, Pennsylvania, specializing in therapeutics for immune-mediated inflammatory diseases, revealed that it is set to join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index. This change will come into effect after the closure of U.S. stock markets on June 26, 2026.

### Related Stocks

- [AVTX.US](https://longbridge.com/en/quote/AVTX.US.md)

## Related News & Research

- [Avalo Therapeutics CFO Christopher Ryan Sullivan disposes of common shares worth $1.44 million](https://longbridge.com/en/news/296395368.md)
- [Avalo Therapeutics posts corporate deck spotlighting IL-1β inhibitor pipeline for hidradenitis suppurativa](https://longbridge.com/en/news/295098964.md)
- [10:31 ETLiver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight](https://longbridge.com/en/news/296802956.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)
- [Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/296455358.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**